4.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:百万円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 20,813 | 17,739 |
受取手形及び売掛金 | ※ 57,409 | 58,780 |
商品及び製品 | 17,824 | 19,114 |
仕掛品 | 11 | 1 |
その他 | 8,084 | 8,206 |
貸倒引当金 | △29 | △23 |
流動資産合計 | 104,114 | 103,819 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 21,126 | 22,606 |
減価償却累計額 | △11,688 | △12,199 |
建物及び構築物(純額) | 9,437 | 10,406 |
土地 | 11,626 | 11,836 |
建設仮勘定 | 711 | 454 |
その他 | 4,306 | 4,703 |
減価償却累計額 | △3,577 | △3,775 |
その他(純額) | 728 | 928 |
有形固定資産合計 | 22,504 | 23,625 |
無形固定資産 | | |
のれん | 851 | 690 |
ソフトウエア | 451 | 464 |
その他 | 359 | 324 |
無形固定資産合計 | 1,662 | 1,478 |
投資その他の資産 | | |
投資有価証券 | 17,720 | 17,038 |
長期売掛金 | 73 | 185 |
長期貸付金 | 229 | 175 |
繰延税金資産 | 322 | 368 |
退職給付に係る資産 | - | 185 |
その他 | 758 | 761 |
貸倒引当金 | △85 | △186 |
投資その他の資産合計 | 19,019 | 18,527 |
固定資産合計 | 43,186 | 43,632 |
資産合計 | 147,300 | 147,451 |
| | (単位:百万円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
負債の部 | | |
流動負債 | | |
支払手形及び買掛金 | ※ 76,015 | 74,995 |
電子記録債務 | ※ 2,488 | 3,008 |
1年内返済予定の長期借入金 | 1 | 1 |
未払法人税等 | 876 | 659 |
賞与引当金 | 974 | 1,022 |
役員賞与引当金 | 134 | 141 |
その他 | 2,699 | 2,518 |
流動負債合計 | 83,191 | 82,346 |
固定負債 | | |
長期借入金 | 13 | 11 |
繰延税金負債 | 2,184 | 2,064 |
再評価に係る繰延税金負債 | 120 | 124 |
退職給付に係る負債 | 94 | 54 |
長期未払金 | 437 | 393 |
資産除去債務 | 340 | 346 |
その他 | 233 | 248 |
固定負債合計 | 3,424 | 3,243 |
負債合計 | 86,616 | 85,590 |
純資産の部 | | |
株主資本 | | |
資本金 | 1,000 | 1,000 |
資本剰余金 | 11,821 | 11,821 |
利益剰余金 | 42,970 | 45,017 |
自己株式 | △2,029 | △2,461 |
株主資本合計 | 53,763 | 55,378 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 7,556 | 7,005 |
土地再評価差額金 | △711 | △715 |
退職給付に係る調整累計額 | 61 | 176 |
その他の包括利益累計額合計 | 6,906 | 6,467 |
非支配株主持分 | 14 | 15 |
純資産合計 | 60,684 | 61,861 |
負債純資産合計 | 147,300 | 147,451 |
E0300330550株式会社ほくやく・竹山ホールディングスHOKUYAKU TAKEYAMA Holdings,inc.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse305502024-03-31tse-acedjpfr-30550:InformationAndCommunicationTechnologyIndustryReportableSegmentsMember305502024-04-012025-03-31tse-acedjpfr-30550:WholesalerOfDrugsIndustryReportableSegmentsMember305502024-04-012025-03-31tse-acedjpfr-30550:MedicalEquipmentWholesaleIndustryReportableSegmentsMember305502024-04-012025-03-31tse-acedjpfr-30550:DispensingIndustryReportableSegmentsMember305502024-04-012025-03-31tse-acedjpfr-30550:NursingIndustryReportableSegmentsMember305502024-04-012025-03-31tse-acedjpfr-30550:InformationAndCommunicationTechnologyIndustryReportableSegmentsMember305502023-04-012024-03-31tse-acedjpfr-30550:WholesalerOfDrugsIndustryReportableSegmentsMember305502023-04-012024-03-31tse-acedjpfr-30550:MedicalEquipmentWholesaleIndustryReportableSegmentsMember305502023-04-012024-03-31tse-acedjpfr-30550:DispensingIndustryReportableSegmentsMember305502023-04-012024-03-31tse-acedjpfr-30550:NursingIndustryReportableSegmentsMember305502023-04-012024-03-31tse-acedjpfr-30550:InformationAndCommunicationTechnologyIndustryReportableSegmentsMember305502025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember305502024-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember305502024-04-012025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember305502023-04-012024-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember305502025-03-31jpcrp_cor:OtherReportableSegmentsMember305502025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember305502025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember305502024-03-31jpcrp_cor:OtherReportableSegmentsMember305502024-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember305502024-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember305502024-04-012025-03-31jpcrp_cor:OtherReportableSegmentsMember305502024-04-012025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember305502024-04-012025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember305502023-04-012024-03-31jpcrp_cor:OtherReportableSegmentsMember305502023-04-012024-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember305502023-04-012024-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember305502025-03-31tse-acedjpfr-30550:WholesalerOfDrugsIndustryReportableSegmentsMember305502025-03-31tse-acedjpfr-30550:MedicalEquipmentWholesaleIndustryReportableSegmentsMember305502025-03-31tse-acedjpfr-30550:DispensingIndustryReportableSegmentsMember305502025-03-31tse-acedjpfr-30550:NursingIndustryReportableSegmentsMember305502025-03-31tse-acedjpfr-30550:InformationAndCommunicationTechnologyIndustryReportableSegmentsMember305502024-03-31tse-acedjpfr-30550:WholesalerOfDrugsIndustryReportableSegmentsMember305502024-03-31tse-acedjpfr-30550:MedicalEquipmentWholesaleIndustryReportableSegmentsMember305502024-03-31tse-acedjpfr-30550:DispensingIndustryReportableSegmentsMember305502024-03-31tse-acedjpfr-30550:NursingIndustryReportableSegmentsMember305502025-03-31jppfs_cor:TreasuryStockMember305502023-03-31jppfs_cor:TreasuryStockMember305502025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember305502023-04-012024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember305502023-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember305502025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember305502024-04-012025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember305502024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember305502023-04-012024-03-31jppfs_cor:NonControllingInterestsMember305502023-03-31jppfs_cor:NonControllingInterestsMember305502023-03-31jppfs_cor:ShareholdersEquityMember305502023-04-012024-03-31jppfs_cor:RetainedEarningsMember305502023-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember305502023-03-31jppfs_cor:RevaluationReserveForLandMember305502023-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember305502023-03-31jppfs_cor:CapitalStockMember305502023-03-31jppfs_cor:CapitalSurplusMember305502023-04-012024-03-31jppfs_cor:TreasuryStockMember305502023-04-012024-03-31jppfs_cor:ShareholdersEquityMember305502023-04-012024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember305502023-04-012024-03-31jppfs_cor:RevaluationReserveForLandMember305502023-04-012024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember305502024-03-31jppfs_cor:CapitalStockMember305502023-03-31jppfs_cor:RetainedEarningsMember305502024-03-31jppfs_cor:CapitalSurplusMember305502024-03-31jppfs_cor:TreasuryStockMember305502025-03-31jppfs_cor:NonControllingInterestsMember305502024-04-012025-03-31jppfs_cor:NonControllingInterestsMember305502024-03-31jppfs_cor:NonControllingInterestsMember305502025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember305502025-03-31jppfs_cor:RevaluationReserveForLandMember305502024-04-012025-03-31jppfs_cor:ShareholdersEquityMember305502024-04-012025-03-31jppfs_cor:CapitalStockMember305502024-04-012025-03-31jppfs_cor:CapitalSurplusMember305502024-04-012025-03-31jppfs_cor:RetainedEarningsMember305502024-04-012025-03-31jppfs_cor:TreasuryStockMember305502024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember305502024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember305502024-03-31jppfs_cor:RetainedEarningsMember305502025-03-31305502024-03-31305502024-04-012025-03-31305502023-04-012024-03-31305502023-03-31305502025-05-15305502024-04-012025-03-31jppfs_cor:RevaluationReserveForLandMember305502023-04-012024-03-31jppfs_cor:CapitalStockMember305502023-04-012024-03-31jppfs_cor:CapitalSurplusMember305502024-03-31jppfs_cor:ShareholdersEquityMember305502024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember305502024-03-31jppfs_cor:RevaluationReserveForLandMember305502024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember305502025-03-31jppfs_cor:ShareholdersEquityMember305502025-03-31jppfs_cor:CapitalStockMember305502025-03-31jppfs_cor:CapitalSurplusMember305502025-03-31jppfs_cor:RetainedEarningsMemberxbrli:pureiso4217:JPY